All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
KPd for patients with early RRMM: Primary analysis from the phase II SELECT trial
Bookmark this article
|
The phase II SELECT trial (NCT04191616) assessed the safety and efficacy of once-weekly carfilzomib plus pomalidomide and dexamethasone (KPd) in 52 adult patients with early relapsed/refractory multiple myeloma (RRMM) who were refractory to lenalidomide.1 Results of the primary analysis from this trial were published in Leukemia & Lymphoma by Perrot, et al.1 |
| Key learnings: |
|
Although the primary endpoint of overall response rate (ORR) was not met, the ORR was 57.7%, with a median duration of response of 20.3 months, highlighting the potential efficacy of KPd in patients with RRMM who are refractory to lenalidomide. |
|
Measurable residual disease (MRD) negativity was achieved in 9.6% of patients, indicating that KPd can effectively reduce MRD to undetectable levels in a subset of patients, a crucial prognostic factor for long-term remission. |
|
The median progression-free survival and overall survival among all patients was 11.1 months and 18.8 months, respectively. |
|
Treatment-emergent adverse events were consistent with the known safety profiles of carfilzomib and pomalidomide, with no new safety signals identified, suggesting that the KPd regimen is a viable option for heavily pretreated patients. |
|
The findings suggest an overall favorable benefit/risk profile of KPd as a salvage therapy for patients with multidrug-resistant RRMM relative to currently available therapies. |
- Perrot A, Delimpasi S, Spanoudakis E, et al. An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study. Leuk Lymphoma. 2024;65(6):833-842. DOI: 1080/10428194.2024.2322030
Your opinion matters
7 votes - 34 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox